Evidence map›Paper›PMID 29021367›Full record

ArticleJournal of leukocyte biology2017

Disruption of Trim9 function abrogates macrophage motility in vivo.

Debra A Tokarz, Amy K Heffelfinger, Dereje D Jima, Jamie Gerlach, Radhika N Shah, Ivan Rodriguez-Nunez, Amanda N Kortum, Ashley A Fletcher, Shila K Nordone, J McHugh Law and 2 more

Abstract read
In one paragraph

Article in Journal of leukocyte biology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. miR-181a Ameliorates the Progression of Myasthenia Gravis by Regulating TRIM9.Evidence-based complementary and alternative medicine : eCAM · 2021
    Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Debra A TokarzDepartment of Molecular Biomedical Sciences, North Carolina State University, Raleigh, North Carolina, USA.
Amy K HeffelfingerDepartment of Molecular Biomedical Sciences, North Carolina State University, Raleigh, North Carolina, USA.
Dereje D JimaDepartment of Molecular Biomedical Sciences, North Carolina State University, Raleigh, North Carolina, USA.
Jamie GerlachDepartment of Molecular Biomedical Sciences, North Carolina State University, Raleigh, North Carolina, USA.
Radhika N ShahDepartment of Molecular Biomedical Sciences, North Carolina State University, Raleigh, North Carolina, USA.
Ivan Rodriguez-NunezDepartment of Molecular Biomedical Sciences, North Carolina State University, Raleigh, North Carolina, USA.
Amanda N KortumDepartment of Molecular Biomedical Sciences, North Carolina State University, Raleigh, North Carolina, USA.
Ashley A FletcherDepartment of Molecular Biomedical Sciences, North Carolina State University, Raleigh, North Carolina, USA.
Shila K NordoneDepartment of Molecular Biomedical Sciences, North Carolina State University, Raleigh, North Carolina, USA.
J McHugh LawComparative Medicine Institute, North Carolina State University, Raleigh, North Carolina, USA.
Steffen HeberDepartment of Computer Science, North Carolina State University, Raleigh, North Carolina, USA.
Jeffrey A YoderDepartment of Molecular Biomedical Sciences, North Carolina State University, Raleigh, North Carolina, USA; jeff_yoder@ncsu.edu.

Funding

Virology Research Program (Program 4)P30CA016086 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Deborah F. Tate · 1985 to 2026
$201.5M
Translational Research Support CoreP30ES025128 · NIEHS · NORTH CAROLINA STATE UNIVERSITY RALEIGH · PI Andrew R. Binder · 2015 to 2026
$18.3M
Comparative Medicine and Translational Research Training ProgramT32OD011130 · OD · NORTH CAROLINA STATE UNIVERSITY RALEIGH · PI Lauren Virginia Schnabel · 2012 to 2026
$7.8M
Molecular Biotechnology Training at North Carolina State UniversityT32GM008776 · NIGMS · NORTH CAROLINA STATE UNIVERSITY RALEIGH · PI KELLY, ROBERT M · 2000 to 2019
$3.9M
Whole organism transcriptional profiling of innate immune responseR21AI076829 · NIAID · NORTH CAROLINA STATE UNIVERSITY RALEIGH · PI YODER, JEFFREY A · 2008 to 2009
$390k
NCI NIH HHS P30 CA016086NIAID NIH HHS R21 AI076829NIEHS NIH HHS P30 ES025128NIGMS NIH HHS T32 GM008776NIH HHS T32 OD011130
6 · The paper itself

Abstract

The vertebrate immune response comprises multiple molecular and cellular components that interface to provide defense against pathogens. Because of the dynamic complexity of the immune system and its interdependent innate and adaptive functionality, an understanding of the whole-organism response to pathogen exposure remains unresolved. Zebrafish larvae provide a unique model for overcoming this obstacle, because larvae are protected against pathogens while lacking a functional adaptive immune system during the first few weeks of life. Zebrafish larvae were exposed to immune agonists for various lengths of time, and a microarray transcriptome analysis was executed. This strategy identified known immune response genes, as well as genes with unknown immune function, including the E3 ubiquitin ligase tripartite motif-9 (

Indexed as

Cell MovementAnimalsCell ShapeChemotaxisHumansMacrophagesNerve Tissue ProteinsRNA, MessengerTripartite Motif ProteinsU937 CellsUbiquitin-Protein LigasesZebrafishZebrafish ProteinsNerve Tissue ProteinsRNA, MessengerTrim9 protein, zebrafishTripartite Motif ProteinsUbiquitin-Protein LigasesZebrafish Proteinschemotaxisleukocyteubiquitinzebrafish

Identifiers

PMID29021367
PMCPMC6608060

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.